Strategic Acquisition Best Formulations was acquired by Sirio Pharma in January 2023, signaling a strategic integration into a larger global contract development and manufacturing network. This presents opportunities to align offerings with Sirio’s expanded capabilities and push for multi-region CDMO partnerships.

Global Reach Post-acquisition, there is potential to leverage Sirio Pharma’s three-continent footprint to offer localized manufacturing solutions, shorten lead times, and optimize supply chains for customers seeking international production and regulatory compliance.

Financial Scale With estimated revenue between $100M and $250M and a sizeable employee base, there's room to pursue larger contract manufacturing programs, custom formulation projects, and premium nutraceutical/pharmaceutical SKU development for growth-focused clients.

Quality Heritage The firm emphasizes uncompromising quality (flagship 20 cu ft PK blender remains a symbol of commitment). This strong quality narrative can be leveraged to win premium projects demanding stringent QA/QC, traceability, and GMP-compliant processes.

Diversified Capabilities As a diversified contract manufacturer serving both nutraceutical and pharmaceutical sectors, Best Formulations can target multi-category brands seeking a single supplier for development, formulation, blending, and manufacturing, facilitating cross-category launches and faster time-to-market.